Caffeine 100-200 mg bid (DrugBank: Caffeine)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
6 | Parkinson disease | 1 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
21 | Mitochondrial disease | 0 |
46 | Malignant rheumatoid arthritis | 0 |
78 | Hypopituitarism | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
265 | Lipodystrophy | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00459420 (ClinicalTrials.gov) | April 2007 | 11/4/2007 | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | Parkinson's Disease;Excessive Daytime Somnolence | Drug: Caffeine 100-200 mg BID;Drug: placebo | Ron Postuma | Canadian Institutes of Health Research (CIHR);University of Toronto | Completed | 18 Years | N/A | Both | 58 | Phase 2;Phase 3 | Canada |